Additional Information
Market: NASDAQ
Sector: Pharmaceuticals
EPIC: BIIB
Latest Price: 345.84  (0.36% Ascending)
52-week High: 351.94
52-week Low: 206.55
Market Cap: 81,668.30M
1 year chart
1 day chart
Biogen Inc
www.biogenidec.com

Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.

Biogen Idec and Roche Meet Primary Endpoint on Phase III Study into Rheumatoid Arthritis Treatment

11th Dec 2009, 1:47 pm
Biogen Idec and Roche Meet Primary Endpoint on Phase III Study into Rheumatoid Arthritis Treatment

Biogen Idec (NASDAQ: BIIB) and Roche Group (OTC: RHHBY, SIX: RO) subsidiary Genentech announced their Phase III study into a treatment for rheumatoid arthritis (RA) patients had met its primary endpoint.


Rheumatoid Arthritis is a debilitating auto-immune disease that affects an estimated 1.3 million Americans. The damage that occurs in RA is a result of the immune system attacking joint tissue, causing painful chronic inflammation and irreversible damage. The disease often results in disability.


"These results are significant because they are the first data from a large Phase III trial to show that a humanized antibody targeted at B-cells improves the signs and symptoms of rheumatoid arthritis", Genentech’s chief medical officer, Hal Barron, M.D commented, "These results build on earlier findings from our broad clinical program”.


Ocrelizumab is an investigational humanized monoclonal antibody. According to the treatment’s development partners, Ocrelizumab selectively binds to and eliminates a particular protein, which is believed to play a critical role in immunologic diseases. Subsequently allowing healthy cells to regenerate after treatment and eventually return to normal levels.


The primary endpoint was to determine the proportion of patients with improving signs and symptoms (as measured by American College of Rheumatology) at week 24 and week 48. The results of three other Phase III studies investigating the use of ocrelizumab in RA are expected in the first half of 2010.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here